Hospitals affiliated with Mount Sinai, the University of Michigan and the University of Kansas allege that CVS artificially ...

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...

CVS Health (NYSE:CVS) has been hit with two lawsuits from major hospital systems tied to the federal 340B drug discount ...

States should stop bolstering a broken program, and Congress must close the loopholes that continue to harm patients.

Three major hospital systems have accused CVS of allegedly diverting hundreds of millions from the federal 340B Drug Pricing ...

Because Cassidy is chair of the Senate Health, Education, Labor, and Pensions committee, his opposition to the program could ...

Three health systems have filed federal lawsuits against CVS Health, alleging the company and several affiliates improperly diverted about $250 million in savings generated through the 340B drug ...

The alleged fraud scheme deprived Mount Sinai of crucial funds meant for vulnerable, uninsured New Yorkers, claims the suit, ...

The pharmaceutical industry won. The hospital industry lost. After a lobbying fight for the ages between the Pharmaceutical ...

Today, 340B functions primarily as a significant revenue stream for large hospital systems, corporate pharmacy chains, and pharmacy benefit managers (PBMs).

Several academic and nonprofit health systems have filed lawsuits against CVS Health, accusing the company and its subsidiaries of improperly pocketing about $250 million of 340B Drug Pricing Program ...

The American Hospital Association expresses concern about Eli Lilly’s January 2026 claims-data policy and invites Lilly to work in good faith with the AHA and our 340B hospital members to find a ...